Business Wire

Western Union Expands Global Real-time Payment Capabilities for Millions of Consumers and Business Accounts

Share

Sibos Conference – Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement, today announced availability of its real-time cross-border platform to accelerate international consumer, consumer-to-business and business-to-consumer payments to eligible accounts, cards and digital wallets. The announcement marks an expansion of Western Union’s unique ability to leverage its core assets – including global settlement capabilities, network, compliance and technology systems – to enable international cross-border payments in minutes across multiple currencies.

Globally recognized for daily cross-currency management and settlement via its vast retail network across 20,000 corridors or pairs of countries for consumers in local currency, the company’s expanded money in minutes platform will now power next-generation cross-border payment experiences for consumers and businesses across a multitude of sectors.

“This is a prime example of how the global reach, inter-connectedness and speed of our platform generate a meaningful customer benefit that is difficult to replicate for cross-border transactions,” said Western Union President and CEO Hikmet Ersek. “Our unique cross-border platform cuts through the international complexities so customers can access their funds in real-time. As we expand from our roots in C2C remittances, we’re positioning ourselves as the platform that powers next-generation payment experiences for businesses and FIs for their diverse cross-border payments needs.”

Western Union’s consumer-to-consumer money in minutes cross-border payments capability is now active when sending to select banks or digital wallet providers in 17countries: Benin, Burundi, Cameroon, China, India, Indonesia, Kenya, Nigeria, Pakistan, Philippines, Sri Lanka, Democratic Republic of Congo, Ghana, Malawi, Mozambique, Zimbabwe, and Uganda. As many as 100 countries are being assessed for enablement of real-time capabilities by the end of 2020.

Accelerating Access to Cross-Border Transfers In-Minutes
From remittances to e-commerce, payroll, real estate and travel, consumer and business expectations for cross-border money movement are changing, driven by the impact of digital on everyday life. Western Union’s platform is uniquely suited to manage the liquidity flows and payment processing needed to accelerate funds in-minutes while also providing consumers and businesses with visibility into the status of their transactions from end to end.

In addition to its expansive digital footprint, settlement and compliance infrastructure, and global retail network with over 550,000 agent locations across 200 countries and territories, Western Union has forged more than 40 banking and payment partnerships in over 100 countries. This robust network of relationships helps accelerate money movement between institutions and provides reliable connections for deposits to billions of customer accounts and digital wallets. As part of this ecosystem, Western Union International Bank (WUIB), an independent banking entity in Europe, plans to enable all European banking partners for real-time deposits during 2020.

Western Union also offers banks a portfolio of application programming interfaces (APIs) to integrate with its cross-border money movement platform, with the added benefit of Western Union’s treasury management, reconciliation and global compliance capabilities.

WU-G

About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of June 30, 2019, our network included over 550,000 retail agent locations offering Western Union, Vigo or Orlandi Valuta branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2018, is available in more than 70 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com.

Contact information

Pia De Lima: +1 954.260.5732 / pia.delima@wu.com
John Derryberry: +1 415.203.8762 / john.derryberry@wu.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting9.12.2019 20:00:00 EETPress release

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today presented data characterizing KB-3061, the lead molecule in the Company’s Kv7 ion channel platform, at the American Epilepsy Society’s (AES) 2019 Annual Meeting in Baltimore, Maryland. Knopp is advancing the development of KB-3061 as a potential precision medicine treatment for the rare, neonatal disease KCNQ2 epileptic encephalopathy (KCNQ2-EE), a genetically defined disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay. The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development. Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE. K

Murray Energy Corporation Posts Information to its Website Related to Murray Metallurgical9.12.2019 18:46:00 EETPress release

Beginning on December 2, 2019, Murray Energy Corporation (the “Company”) engaged in confidential discussions under separate confidentiality agreements with certain members of an ad hoc group of superpriority lenders related Murray Metallurgical Coal Holdings, LLC and its subsidiaries (collectively, “Murray Metallurgical”). The confidentiality agreements require the Company to publicly disclose all material non-public information provided to such lenders on or prior to 8:30am (New York time) on December 9, 2019. The Company has posted certain previously undisclosed material to its website to satisfy its disclosure obligations under the confidentiality agreements. Such information can be viewed at the Investors portion of the Company’s website, located at murrayenergycorp.com/investors. Further inquiries should be directed to media@coalsource.com. Safe Harbor Statement The materials referenced in this release and posted to our website include forward-looking statements. A variety of fact

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 20199.12.2019 18:00:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable improved treatment outcomes. Insights presented at ASH include: ADYNOVATE ® [Antihemophilic Factor (Recombinant), PEGylated]: In the poster “Real-World Age-Stratified FVIII Consumption and Bleed Outcom

Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting9.12.2019 18:00:00 EETPress release

Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas (PTCL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005169/en/ The ECHELON-1 analysis highlighted a four-year update of the phase 3 clinical trial in a poster presentation. ECHELON-1 is evaluating ADCETRIS in combination with AVD (Adriamycin [doxorubicin], vinblastine and dacarbazine) compared to ABVD (Adriamycin [doxorubicin], bleomycin, vinblasti

Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding9.12.2019 17:39:00 EETPress release

Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose. The grant was made to Indivior by the NIH in fiscal year 2019, to apply scientific solutions to reverse the national opioid crisis. In March 2018, Indivior entered into a license agreement with C4X Discovery Holdings PLC (C4X) whereby Indivior obtained exclusive global rights to develop and commercialize INDV-2000 (C4X_3256). The first-in-human, single-ascending-dose study will be conducted in two parts — Part I: double-blind, placebo-controlled, randomized, single-ascending-dose study in fasted condition. Part II:

Elliott Statement on Alexion9.12.2019 17:22:00 EETPress release

Funds advised by Elliott Advisors (UK) Limited (together “Elliott” or “we”) acknowledge the statement issued by Alexion Pharmaceuticals, Inc. (“Alexion” or “the Company”) on Friday. Elliott confirms that it has had a multiyear, constructive and private engagement with Alexion that has led to value-creative changes at the Company. Despite two years of strong execution that bolstered the Company’s strategic value, we believe Alexion remains significantly undervalued by the market. Elliott is encouraged by the Board’s public commitment to evaluate any inbound interest and its overall commitment to shareholder value creation. Elliott remains of the view that Alexion would be a highly valuable strategic and financial asset for a number of larger pharmaceutical companies. We also continue to believe that a proactive approach would maximise the chance of an optimal outcome. We look forward to continuing our dialogue with the Company in an effort to close the gap between its current share pric

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom